Evidence Hub

Evaluation of Fibronectin, C-Reactive Protein and Lipid Profile in Patients with COVID-19

Nagham I. Abdul Hameed, Zina A. A. Aldoori

Haya The Saudi Journal of Life Sciences, 2024

Abstract

The SARS-CoV-2 coronavirus was the initial cause of the worldwide epidemic of coronavirus disease 2019 (COVID-19), which started in March of 2020. Patients with coronavirus disease (COVID-19) may have elevated C-reactive protein (CRP) and fibronectin levels owing to the inflammatory response caused by the virus. Nonetheless, the available data imply that infection with COVID-19 affects lipid profile and leads to dyslipidemia. Seventy samples were collected from the Sanitary Isolation Unit of Medical City Hospital in Kirkuk Governorate for this study. Forty of them were taken from SARS-COV2 patients, whereas the other thirty were from healthy individuals. The ages of the two groups ranged between (30-65) years. When a real-time polymerase chain reaction (PCR) tested positive, patients had blood collected to check for other biochemical and inflammatory markers. Fibronectin, C-reactive protein, and d-dimer were some of the indicators checked. The patients' blood was also analyzed for lipids such as total cholesterol (T.C), triacylglyceride (TG), Low-Density Lipoprotein Cholesterol, and High-Density Lipoprotein Cholesterol (HDL-C). In this study, researchers discovered abnormally high concentrations of CRP, D-dimer, fibronectin, triglycerides, LDL-C, and VLDL. The patients also had considerably lower levels of T.C and HDL-C compared to the controls.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free